Description
The Partnering Agreements with Bigpharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.
This premier report provides all the information you require to better understand bigpharma partnering.
One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 200 charts allow quick understanding of each bigpharma companies dealmaking trends over the last four years.
This report contains over 1,200 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of bigpharma’s dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2008 pharmaceutical revenues and dealmaking activity since 2005.
Chapter 3 analyzes the most active dealmakers since 2005 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-2009 according to reported deal size.
Chapter 5 provides a summary on best practice on how to submit an opportunity to bigpharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.
Chapter 6 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.
The main body of the report is provided in chapter 7 and 8.
Firstly, a series of matrices provide a cross reference for each bigpharma company versus therapy area with respect to marketed and pipeline activity, partnering interests, and partnering activity in the last three years.
Secondly, in-depth profiles of every bigpharma company provide everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company’s marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. Each profile also includes in-depth contact information for individuals within the business development function.
In addition, each company profile provides a listing of deal contract documents available in the public domain, each of which links direct to an online copy of the actual contract document as filed with the SEC.
Key benefits
Partnering Agreements with Bigpharma provides the user with the following Key benefits:
* Detailed company profiles for each of the top 50 bigpharma companies
* Over 200 charts showing a company’s dealmaking activity since 2005, allowing quick identification potential partners
* In-depth marketed and pipeline product activity of each company
* Partnering interests and therapy focus revealed
* Partnering activity since 2000 – number of deals per year
* Partnering activity for 2005-2009
* Activity by deal type
* Activity by phase of development
* Activity by therapeutic area
* List of recent partner companies
* Comprehensive access to over 1,200 actual contracts entered into by the leading fifty biopharma companies
* Insight into the terms included in a partnering agreement, together with real world clause examples
* Understand the key deal terms the company has agreed in previous deals
* Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Partnering Agreements with Bigpharma is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s approach to partnering.
Partnering Agreements with Bigpharma includes:
* Detailed company profiles for each of the top 50 bigpharma companies, including:
* Full contact details
* Business developer contact details including name, title, email and telephone (where available)
* Marketed indications
* Pipeline indications
* Partnering interests and indications
* Partnering activity since 2000
* Current partner companies since 2005
* Partnering activity since 2005 by:
* Deal type
* Stage of development
* Therapy area
* Over 200 charts showing the dealmaking activity of each company since 2005
* The tools to enable effective and efficient preparation for partnering negotiation with bigpharma
* Listing of over 1,200 contract documents between bigpharma and partner companies
* The leading M&A and partnering deals by value 2005-2009
* Most active M&A and partnering dealmakers 2005-2009
The Partnering Agreements with Bigpharma report also provides comprehensive access to available contract documents for each of the fifty bigpharma companies. Analyzing actual company agreements allows assessment of the following:
* What is actually granted by the agreement to the partner company?
* What exclusivity is granted?
* What is the payment structure for the deal?
* How are sales and payments audited?
* What is the deal term?
* How are the key terms of the agreement defined?
* How are IPRs handled and owned?
* Who is responsible for commercialization?
* Who is responsible for development, supply, and manufacture?
* How is confidentiality and publication managed?
* How are disputes to be resolved?
* Under what conditions can the deal be terminated?
* What happens when there is a change of ownership?
* What sublicensing and subscontracting provisions have been agreed?
* Which boilerplate clauses does the company insist upon?
* Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
* Which jurisdiction does the company insist upon for agreement law?
For each company in Partnering Agreements with Bigpharma report, the available contracts are listed by deal type, including:
* Co-development
* Co-marketing
* Co-promotion
* Collaborative R&D
* Development
* Distribution
* Joint venture
* Licensing
* M&A
* Manufacturing
* Marketing
* Promotion
* Research
* Supply
Pharmaceutical Industry
Table of contents
Number of pages: 656
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Bigpharma top 50 and their dealmaking activity
Chapter 3 – Most active bigpharma dealmakers
* 3.1 Bigpharma M&A activity
* 3.2 Bigpharma partnering
Chapter 4 – Top bigpharma deals by value
* 4.1 Bigpharma M&A
* 4.2 Bigpharma partnering
Chapter 5 – Submitting Opportunities to Bigpharma
* 5.1 How to submit an opportunity
* 5.2 Opportunity submission template
* 5.3 Sending emails
* 5.4 Face to face at partnering events
* 5.5 Online submission forms
Chapter 6 – Forthcoming bigpharma partnering events
* 6.1 Forthcoming events
Chapter 7 – Bigpharma company – therapy locator
* 7.1 How to use the therapy matrix tables
* 7.2 Therapeutic area definitions
* 7.3 Bigpharma – Therapeutic target matrix – marketed and pipeline compounds
* 7.4 Bigpharma – Therapeutic target matrix – expressed partnering interests
* 7.5 Bigpharma – Therapeutic target matrix – recent deals – 2005-2009
Chapter 8 – Bigpharma Company Profiles
* 8.1 How to use company profiles
* 8.2 Field definitions
* 8.3 Company profiles
* Abbott
* Actavis
* Alcon Labs
* Allergan
* Amgen
* Astellas
* AstraZeneca
* Baxter
* Bayer
* Biogen Idec
* Boehringer Ingelheim
* Bristol-Myers Squibb
* Cephalon
* Chugai
* CSL
* Daiichi Sankyo
* Dainnipon Sumitomo
* Eisai
* Eli Lilly
* Forest Laboratories
* Genentech
* Genzyme
* Gilead Sciences
* GlaxoSmithKline
* Hospira
* Johnson & Johnson
* Lundbeck
* Menarini
* Merck & Co
* Merck Serono
* Mitsubishi-Tanabe
* Mylan
* Novartis
* Novo Nordisk
* Nycomed Pharma
* Otsuka
* Pfizer
* Procter & Gamble
* Ratiopharm
* Roche
* Sanofi-Aventis
* Schering Plough
* Servier
* Shire
* Solvay
* Takeda
* Teva
* UCB
* Watson
* Wyeth
Chapter 9 – Resources
Table of contents
* Figure 1: Bigpharma – top 50 by pharma sales
* Figure 2: Leading Bigpharma M&A companies, 2005-2009
* Figure 3: Bigpharma M&A activity – top 50 by pharma sales
* Figure 4: Leading Bigpharma partnering companies, 2005-2009
* Figure 5: Bigpharma partnering activity – top 50 by pharma sales
* Figure 6: Leading M&A deals involving bigpharma by value, 2005-2009
* Figure 7: Leading partnering deals by value, 2005-2009
* Figure 8: Typical partnering opportunity submission template
* Figure 10: Therapeutic area definitions 36
* Figure 11: Therapeutic target matrix – marketed and pipeline compounds
* Figure 12: Therapeutic target matrix – expressed partnering interests
* Figure 13: Therapeutic target matrix – recent deals 2005-2009
* Figure 14: Company profile template and definitions used in report
* Figure 15: Abbott – Dealmaking frequency 2000-2009
* Figure 16: Abbott - recent deals (2005-2009) by deal type
* Figure 17: Abbott - recent deals (2005 – 2009) by stage of development
* Figure 18: Abbott – recent deals (2005 – 2009) by therapy area
* Figure 19: Recent Abbott partnering deals (2003-2009) where contract document available
* Figure 20: Actavis – Dealmaking frequency 2000-2009
* Figure 21: Actavis - recent deals (2005-2009) by deal type
* Figure 22: Actavis - recent deals (2005 – 2009) by stage of development
* Figure 23: Actavis – recent deals (2005 – 2009) by therapy area
* Figure 24: Recent Actavis partnering deals (2003-2009) where contract document available
* Figure 25: Alcon Labs dealmaking frequency 2000-2009
* Figure 26: Alcon Labs - recent deals (2005 - 2009) by deal type
* Figure 27: Alcon Labs - recent deals (2005 – 2009) by stage of development
* Figure 28: Alcon Labs – recent deals (2005 – 2009) by therapy area
* Figure 29: Recent Alcon Labs partnering deals (2003-2009) where contract document available
* Figure 30: Allergan – Dealmaking frequency 2000-2009
* Figure 31: Allergan - recent deals (2005-2009) by deal type
* Figure 32: Allergan - recent deals (2005 – 2009) by stage of development
* Figure 33: Allergan – recent deals (2005 – 2009) by therapy area
* Figure 34: Recent Allergan partnering deals (2003-2009) where contract document available
* Figure 35: Amgen – Dealmaking frequency 2000-2009
* Figure 36: Amgen - recent deals (2005-2009) by deal type
* Figure 37: Amgen - recent deals (2005 – 2009) by stage of development
* Figure 38: Amgen – recent deals (2005 – 2009) by therapy area
* Figure 39: Recent Amgen partnering deals (2003-2009) where contract document available
* Figure 40: Astellas – Dealmaking frequency 2000-2009
* Figure 41: Astellas - recent deals (2005-2009) by deal type
* Figure 42: Astellas - recent deals (2005 – 2009) by stage of development
* Figure 43: Astellas – recent deals (2005 – 2009) by therapy area
* Figure 44: Recent Astellas partnering deals (2003-2009) where contract document available
* Figure 45: AstraZeneca – Dealmaking frequency 2000-2009
* Figure 46: AstraZeneca - recent deals (2005-2009) by deal type
* Figure 47: AstraZeneca - recent deals (2005 – 2009) by stage of development
* Figure 48: AstraZeneca – recent deals (2005 – 2009) by therapy area
* Figure 49: Recent AstraZeneca partnering deals (2003-2009) where contract document available
* Figure 50: Baxter – Dealmaking frequency 2000-2009
* Figure 51: Baxter - recent deals (2005-2009) by deal type
* Figure 52: Baxter - recent deals (2005 – 2009) by stage of development
* Figure 53: Baxter – recent deals (2005 – 2009) by therapy area
* Figure 54: Recent Baxter partnering deals (2003-2009) where contract document available
* Figure 55: Bayer – Dealmaking frequency 2000-2009
* Figure 56: Bayer - recent deals (2005-2009) by deal type
* Figure 57: Bayer - recent deals (2005 – 2009) by stage of development
* Figure 58: Bayer – recent deals (2005 – 2009) by therapy area
* Figure 59: Recent Bayer partnering deals (2003-2009) where contract document available
* Figure 60: Biogen Idec – Dealmaking frequency 2000-2009
* Figure 61: Biogen Idec - recent deals (2005 – 2009) by deal type
* Figure 62: Biogen Idec - recent deals (2005 – 2009) by stage of development
* Figure 63: Biogen Idec – recent deals (2005 – 2009) by therapy area
* Figure 64: Recent Biogen Idec partnering deals (2003-2009) where contract document available
* Figure 65: Boehringer Ingelheim – Dealmaking frequency 2000-2009
* Figure 66: Boehringer Ingelheim - recent deals (2005 – 2009) by deal type
* Figure 67: Boehringer Ingelheim - recent deals (2005 – 2009) by stage of development
* Figure 68: Boehringer Ingelheim – recent deals (2005 – 2009) by therapy area
* Figure 69: Recent Boehringer Ingelheim partnering deals (2003-2009) where contract document available
* Figure 70: Bristol-Myers Squibb – Dealmaking frequency 2000-2009
* Figure 71: Bristol-Myers Squibb - recent deals (2005 – 2009) by deal type
* Figure 72: Bristol-Myers Squibb - recent deals (2005 – 2009) by stage of development
* Figure 73: Bristol-Myers Squibb – recent deals (2005 – 2009) by therapy area
* Figure 74: Recent Bristol-Myers Squibb partnering deals (2003-2009) where contract document available
* Figure 75: Cephalon – Dealmaking frequency 2000-2009
* Figure 76: Cephalon - recent deals (2005-2009) by deal type
* Figure 77: Cephalon - recent deals (2005 – 2009) by stage of development
* Figure 78: Cephalon – recent deals (2005 – 2009) by therapy area
* Figure 79: Recent Cephalon partnering deals (2003-2009) where contract document available
* Figure 80: Chugai – Dealmaking frequency 2000-2009
* Figure 81: Chugai - recent deals (2005-2009) by deal type
* Figure 82: Chugai - recent deals (2005 – 2009) by stage of development
* Figure 83: Chugai – recent deals (2005 – 2009) by therapy area
* Figure 84: Recent Chugai partnering deals (2003-2009) where contract document available
* Figure 85: CSL – Dealmaking frequency 2000-2009
* Figure 86: CSL - recent deals (2005-2009) by deal type
* Figure 87: CSL - recent deals (2005 – 2009) by stage of development
* Figure 88: CSL – recent deals (2005 – 2009) by therapy area
* Figure 89: Recent CSL partnering deals (2003-2009) where contract document available
* Figure 90: DaiichiSankyo – Dealmaking frequency 2000-2009
* Figure 91: DaiichiSankyo - recent deals (2005-2009) by deal type
* Figure 92: DaiichiSankyo - recent deals (2005 – 2009) by stage of development
* Figure 93: DaiichiSankyo – recent deals (2005 – 2009) by therapy area
* Figure 94: Recent DaiichSankyo partnering deals (2003-2009) where contract document available
* Figure 95: Dainippon Sumitomo – Dealmaking frequency 2000-2009
* Figure 96: Dainippon Sumitomo - recent deals (2005-2009) by deal type
* Figure 97: Dainippon Sumitomo - recent deals (2005 – 2009) by stage of development
* Figure 98: Dainippon Sumitomo – recent deals (2005 – 2009) by therapy area
* Figure 99: Recent Dainippon Sumitomo partnering deals (2003-2009) where contract document available
* Figure 100: Eisai – Dealmaking frequency 2000-2009
* Figure 101: Eisai - recent deals (2005-2009) by deal type
* Figure 102: Eisai - recent deals (2005 – 2009) by stage of development
* Figure 103: Eisai – recent deals (2005 – 2009) by therapy area
* Figure 104: Recent Eisai partnering deals (2003-2009) where contract document available
* Figure 105: Eli Lilly – Dealmaking frequency 2000-2009
* Figure 106: Eli Lilly - recent deals (2005-2009) by deal type
* Figure 107: Eli Lilly - recent deals (2005 – 2009) by stage of development
* Figure 108: Eli Lilly – recent deals (2005 – 2009) by therapy area
* Figure 109: Recent Eli Lilly partnering deals (2003-2009) where contract document available
* Figure 110: Forest – Dealmaking frequency 2000-2009
* Figure 111: Forest - recent deals (2005-2009) by deal type
* Figure 112: Forest - recent deals (2005 – 2009) by stage of development
* Figure 113: Forest – recent deals (2005 – 2009) by therapy area
* Figure 114: Recent Forest partnering deals (2003-2009) where contract document available
* Figure 115: Genentech – Dealmaking frequency 2000-2009
* Figure 116: Genentech - recent deals (2005-2009) by deal type
* Figure 117: Genentech - recent deals (2005 – 2009) by stage of development
* Figure 118: Genentech – recent deals (2005 – 2009) by therapy area
* Figure 119: Recent Genentech partnering deals (2003-2009) where contract document available
* Figure 120: Genzyme – Dealmaking frequency 2000-2009
* Figure 121: Genzyme - recent deals (2005-2009) by deal type
* Figure 122: Genzyme - recent deals (2005 – 2009) by stage of development
* Figure 123: Genzyme – recent deals (2005 – 2009) by therapy area
* Figure 124: Recent Genzyme partnering deals (2003-2009) where contract document available
* Figure 125: Gilead – Dealmaking frequency 2000-2009
* Figure 126: Gilead - recent deals (2005-2009) by deal type
* Figure 127: Gilead - recent deals (2005 – 2009) by stage of development
* Figure 128: Gilead – recent deals (2005 – 2009) by therapy area
* Figure 129: Recent Gilead partnering deals (2003-2009) where contract document available
* Figure 130: GlaxoSmithKline – Dealmaking frequency 2000-2009
* Figure 131: GlaxoSmithKline - recent deals (2005-2009) by deal type
* Figure 132: GlaxoSmithKline - recent deals (2005 – 2009) by stage of development
* Figure 133: GlaxoSmithKline – recent deals (2005 – 2009) by therapy area
* Figure 134: Recent GlaxoSmithKline partnering deals (2003-2009) where contract document available
* Figure 135: Hospira – Dealmaking frequency 2000-2009
* Figure 136: Hospira - recent deals (2005-2009) by deal type
* Figure 137: Hospira - recent deals (2005 – 2009) by stage of development
* Figure 138: Hospira – recent deals (2005 – 2009) by therapy area
* Figure 139: Recent Hospira partnering deals (2003-2009) where contract document available
* Figure 140: Johnson & Johnson – Dealmaking frequency 2000-2009
* Figure 141: Johnson & Johnson - recent deals (2005-2009) by deal type
* Figure 142: Johnson & Johnson - recent deals (2005 – 2009) by stage of development
* Figure 143: Johnson & Johnson – recent deals (2005 – 2009) by therapy area
* Figure 144: Recent Johnson & Johnson partnering deals (2003-2009) where contract document available
* Figure 145: Lundbeck – Dealmaking frequency 2000-2009
* Figure 146: Lundbeck - recent deals (2005-2009) by deal type
* Figure 147: Lundbeck - recent deals (2005 – 2009) by stage of development
* Figure 148: Lundbeck – recent deals (2005 – 2009) by therapy area
* Figure 149: Recent Lundbeck partnering deals (2003-2009) where contract document available
* Figure 150: Menarini – Dealmaking frequency 2000-2009
* Figure 151: Menarini - recent deals (2005-2009) by deal type
* Figure 152: Menarini - recent deals (2005 – 2009) by stage of development
* Figure 153: Menarini – recent deals (2005 – 2009) by therapy area
* Figure 154: Recent Menarini partnering deals (2003-2009) where contract document available
* Figure 155: Merck & Co – Dealmaking frequency 2000-2009
* Figure 156: Merck & Co - recent deals (2005-2009) by deal type
* Figure 157: Merck & Co - recent deals (2005 – 2009) by stage of development
* Figure 158: Merck & Co – recent deals (2005 – 2009) by therapy area
* Figure 159: Recent Merck & Co partnering deals (2003-2009) where contract document available
* Figure 160: Merck KGaA – Dealmaking frequency 2000-2009
* Figure 161: Merck KGaA - recent deals (2005-2009) by deal type
* Figure 162: Merck KGaA - recent deals (2005 – 2009) by stage of development
* Figure 163: Merck KGaA – recent deals (2005 – 2009) by therapy area
* Figure 164: Recent Merck KGaA partnering deals (2003-2009) where contract document available
* Figure 165: Mitsubishi-Tanabe – Dealmaking frequency 2000-2009
* Figure 166: Mitsubishi-Tanabe - recent deals (2005-2009) by deal type
* Figure 167: Mitsubishi-Tanabe - recent deals (2005 – 2009) by stage of development
* Figure 168: Mitsubishi-Tanabe – recent deals (2005 – 2009) by therapy area
* Figure 169: Recent Mitsubishi-Tanabe partnering deals (2003-2009) where contract document available
* Figure 170: Mylan – Dealmaking frequency 2000-2009
* Figure 171: Mylan - recent deals (2005-2009) by deal type
* Figure 172: Mylan - recent deals (2005 – 2009) by stage of development
* Figure 173: Mylan – recent deals (2005 – 2009) by therapy area
* Figure 174: Recent Mylan partnering deals (2003-2009) where contract document available
* Figure 175: Novartis – Dealmaking frequency 2000-2009
* Figure 176: Novartis - recent deals (2005-2009) by deal type
* Figure 177: Novartis - recent deals (2005 – 2009) by stage of development
* Figure 178: Novartis – recent deals (2005 – 2009) by therapy area
* Figure 179: Recent Novartis partnering deals (2003-2009) where contract document available
* Figure 180: Novo Nordisk – Dealmaking frequency 2000-2009
* Figure 181: Novo Nordisk - recent deals (2005-2009) by deal type
* Figure 182: Novo Nordisk - recent deals (2005 – 2009) by stage of development
* Figure 183: Novo Nordisk – recent deals (2005 – 2009) by therapy area
* Figure 184: Recent Novo Nordisk partnering deals (2003-2009) where contract document available
* Figure 185: Nycomed – Dealmaking frequency 2000-2007
* Figure 186: Nycomed - recent deals (2005-2008) by deal type
* Figure 187: Nycomed - recent deals (2005 – 2009) by stage of development
* Figure 188: Nycomed – recent deals (2005 – 2009) by therapy area
* Figure 189: Recent Nycomed partnering deals (2003-2009) where contract document available
* Figure 190: Otsuka – Dealmaking frequency 2000-2009
* Figure 191: Otsuka - recent deals (2005-2009) by deal type
* Figure 192: Otsuka - recent deals (2005 – 2009) by stage of development
* Figure 193: Otsuka – recent deals (2005 – 2009) by therapy area
* Figure 194: Recent Otsuka partnering deals (2003-2009) where contract document available
* Figure 195: Pfizer – Dealmaking frequency 2000-2009
* Figure 196: Pfizer - recent deals (2005-2009) by deal type
* Figure 197: Pfizer - recent deals (2005 – 2009) by stage of development
* Figure 198: Pfizer – recent deals (2005 – 2009) by therapy area
* Figure 199: Recent Pfizer partnering deals (2003-2009) where contract document available
* Figure 200: Procter & Gamble – Dealmaking frequency 2000-2009
* Figure 201: Procter & Gamble - recent deals (2005-2009) by deal type
* Figure 202: Procter & Gamble - recent deals (2005 – 2009) by stage of development
* Figure 203: Procter & Gamble – recent deals (2005 – 2009) by therapy area
* Figure 204: Recent Procter & Gamble partnering deals (2003-2009) where contract document available
* Figure 205: Ratiopharm – Dealmaking frequency 2000-2009
* Figure 206: Ratiopharm - recent deals (2005-2009) by deal type
* Figure 207: Ratiopharm - recent deals (2005 – 2009) by stage of development
* Figure 208: Ratiopharm – recent deals (2005 – 2009) by therapy area
* Figure 209: Recent Ratiopharm partnering deals (2003-2009) where contract document available
* Figure 210: Roche – Dealmaking frequency 2000-2009
* Figure 211: Roche - recent deals (2005-2009) by deal type
* Figure 212: Roche - recent deals (2005 – 2009) by stage of development
* Figure 213: Roche – recent deals (2005 – 2009) by therapy area
* Figure 214: Recent Roche partnering deals (2003-2009) where contract document available
* Figure 215: Sanofi-Aventis – Dealmaking frequency 2000-2009
* Figure 216: Sanofi-Aventis - recent deals (2005-2009) by deal type
* Figure 217: Sanofi-Aventis - recent deals (2005 – 2009) by stage of development
* Figure 218: Sanofi-Aventis – recent deals (2005 – 2009) by therapy area
* Figure 219: Recent Sanofi-Aventis partnering deals (2003-2009) where contract document available
* Figure 219: Schering Plough – Dealmaking frequency 2000-2009
* Figure 220: Schering Plough - recent deals (2005-2009) by deal type
* Figure 221: Schering Plough - recent deals (2005 – 2009) by stage of development
* Figure 222: Schering Plough – recent deals (2005 – 2009) by therapy area
* Figure 223: Recent Schering Plough partnering deals (2003-2009) where contract document available
* Figure 225: Servier – Dealmaking frequency 2000-2009
* Figure 226: Servier - recent deals (2005-2009) by deal type
* Figure 227: Servier - recent deals (2005 – 2009) by stage of development
* Figure 228: Servier – recent deals (2005 – 2009) by therapy area
* Figure 229: Recent Servier partnering deals (2003-2009) where contract document available
* Figure 230: Shire – Dealmaking frequency 2000-2009
* Figure 231: Shire - recent deals (2005-2009) by deal type
* Figure 232: Shire - recent deals (2005 – 2009) by stage of development
* Figure 233: Shire – recent deals (2005 – 2009) by therapy area
* Figure 234: Recent Shire partnering deals (2003-2009) where contract document available
* Figure 235: Solvay – Dealmaking frequency 2000-2009
* Figure 236: Solvay - recent deals (2005-2009) by deal type
* Figure 237: Solvay - recent deals (2005 – 2009) by stage of development
* Figure 238: Solvay – recent deals (2005 – 2009) by therapy area
* Figure 239: Recent Solvay partnering deals (2003-2009) where contract document available
* Figure 240: Takeda – Dealmaking frequency 2000-2009
* Figure 241: Takeda - recent deals (2005-2009) by deal type
* Figure 242: Takeda - recent deals (2005 – 2009) by stage of development
* Figure 243: Takeda – recent deals (2005 – 2009) by therapy area
* Figure 244: Recent Takeda partnering deals (2003-2009) where contract document available
* Figure 245: Teva – Dealmaking frequency 2000-2009
* Figure 246: Teva - recent deals (2005-2009) by deal type
* Figure 247: Teva - recent deals (2005 – 2009) by stage of development
* Figure 248: Teva – recent deals (2005 – 2009) by therapy area
* Figure 249: Recent Teva partnering deals (2003-2009) where contract document available
* Figure 250: UCB Group – Dealmaking frequency 2000-2009
* Figure 251: UCB Group - recent deals (2005-2009) by deal type
* Figure 252: UCB Group - recent deals (2005 – 2009) by stage of development
* Figure 253: UCB Group – recent deals (2005 – 2009) by therapy area
* Figure 254: Recent UCB Group partnering deals (2003-2009) where contract document available
* Figure 255: Watson – Dealmaking frequency 2000-2009
* Figure 256: Watson - recent deals (2005-2009) by deal type
* Figure 257: Watson - recent deals (2005 – 2009) by stage of development
* Figure 258: Watson – recent deals (2005 – 2009) by therapy area
* Figure 259: Recent Watson partnering deals (2003-2009) where contract document available
* Figure 260: Wyeth – Dealmaking frequency 2000-2009
* Figure 261: Wyeth - recent deals (2005-2009) by deal type
* Figure 262: Wyeth - recent deals (2005 – 2009) by stage of development
* Figure 263: Wyeth – recent deals (2005 – 2009) by therapy area
* Figure 264: Recent Wyeth partnering deals (2003-2009) where contract document available
* Figure 265: Online partnering resources
* Figure 266: Collaborative R&D and license agreement between GlaxoSmithKline and Supergen, November 2009
